| __timestamp | GSK plc | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 3450000000 | 33472000 |
| Thursday, January 1, 2015 | 3560000000 | 47368000 |
| Friday, January 1, 2016 | 3628000000 | 66871000 |
| Sunday, January 1, 2017 | 4476000000 | 50675000 |
| Monday, January 1, 2018 | 3893000000 | 78821000 |
| Tuesday, January 1, 2019 | 4568000000 | 91944000 |
| Wednesday, January 1, 2020 | 5098000000 | 111234000 |
| Friday, January 1, 2021 | 5278000000 | 207447000 |
| Saturday, January 1, 2022 | 5488000000 | 267587000 |
| Sunday, January 1, 2023 | 6223000000 | 303055000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, GSK plc and HUTCHMED (China) Limited have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, GSK's R&D expenses surged by approximately 80%, peaking at over $6 billion in 2023. This reflects GSK's robust strategy to maintain its competitive edge in the global market. In contrast, HUTCHMED's R&D spending, while significantly smaller, has grown nearly tenfold, highlighting its aggressive push to expand its footprint in the pharmaceutical industry. This comparison underscores the diverse strategies companies employ to drive innovation and growth, with GSK focusing on sustained investment and HUTCHMED on rapid expansion.
R&D Spending Showdown: Merck & Co., Inc. vs GSK plc
Analyzing R&D Budgets: Amgen Inc. vs HUTCHMED (China) Limited
Research and Development Investment: GSK plc vs Opthea Limited
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Alpine Immune Sciences, Inc.
R&D Insights: How GSK plc and Protagonist Therapeutics, Inc. Allocate Funds
Takeda Pharmaceutical Company Limited or HUTCHMED (China) Limited: Who Invests More in Innovation?
Biogen Inc. or HUTCHMED (China) Limited: Who Invests More in Innovation?
Comparing Innovation Spending: Madrigal Pharmaceuticals, Inc. and HUTCHMED (China) Limited
Research and Development Investment: Grifols, S.A. vs HUTCHMED (China) Limited
Research and Development Expenses Breakdown: Viking Therapeutics, Inc. vs HUTCHMED (China) Limited
Research and Development Expenses Breakdown: Vericel Corporation vs HUTCHMED (China) Limited
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Geron Corporation